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Natural products containing derivatives of the basic indole backbone have gained 
significant interest in the use against cancer cells, inflammation, and a multitude of 
disorders in the human body. The indole backbone is present in several endogenous 
hormones such as serotonin and melatonin. Additionally, the indole-containing amino 
acid tryptophan is the starting structure for many endogenous metabolites controlling 
natural physiological homeostasis such as circadian rhythms, healthy gut microbiota, and 
gut health. Natural indirubin is a deep red bis-indole isomer of indigo blue, both of which 
are biologically active ingredients used to treat neoplasia, chronic inflammation, and 
enhance xenobiotics' detoxification. Naturally derived indirubins and other indole-
containing compounds have been shown to have anti-proliferative effects, mainly 
attributed to the inhibition of the cell cycle-related kinases, such as cyclin-dependent 
kinases (CDKs) and glycogen synthase kinase-3b (GSK-3b ) with varying degrees of 
potency. Many indirubins are also aryl hydrocarbon receptor (AHR) agonists, with AHR-
associated activities covering a wide range of potencies, depending on molecular 
structure. The AHR is a ligand-activated transcription factor that promotes drug-
metabolizing enzymes leading to the degradation of these indirubins in an AHR-
dependent manner. Our lab previously described the anti-inflammatory properties of 
indirubin-3'-(2,3 dihydroxypropyl)-oximether (E804), a novel indirubin derivative with 
potent STAT3 inhibitory properties, in murine RAW264.7 macrophages stimulated with 
lipopolysaccharide (LPS). This study compared the effects of a novel STAT3 inhibitor, 6-
nitrobenzo[b]thiophene 1,1-dioxide (STATTIC), which is structurally designed as an 
 iii 
indole backbone to E804, on LPS-stimulated macrophage functions. I also determined if 
the effects of both STATTIC and E804 on these macrophage functions are modified by 
the AHR antagonist, 6,2’,4’-trimethoxyflavone (TMF). Initial studies using AHR reporter 
transactivation assays show that E804, but not STATTIC or TMF, is an AHR agonist, 
which further corroborates early studies showing that E804 induces the drug-
metabolizing monooxygenases (CYP1A1 and CYP1B1). Additionally, I demonstrate that 
STATTIC is more potent than E804 in suppressing LPS-induced IL-6 secretion, iNOS 
protein expression, and nitric oxide production. Macrophage intracellular reactive oxygen 
species (ROS) naturally generated during LPS-stimulation was suppressed by low levels 
of STATTIC but not by higher levels. In contrast, similar concentrations of E804 
suppress ROS production. STATTIC completely inhibited phagocytosis, and less so by 
E804. When examined alone, TMF has anti-inflammatory properties as well, and when 
combined with E804 and STATTIC, further enhanced these compounds’ effects. 
Collectively, these results indicate that E804 and STATTIC are potent modulators of pro-
inflammatory profiles in LPS-treated macrophages. Additionally, these results suggest 
that AHR antagonism by TMF may antagonize the degradation of E804 and prolong its 
anti-inflammatory properties. Since STATTIC did not bind the AHR, any treatments 
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Macrophages in Inflammation  
 Inflammation is a complex response to protect the body from a broad range of 
insults ranging from toxic substances to invading pathogens. Acute inflammation is 
beneficial in destroying local pathogen invaders, but a sustained chronic inflammatory 
response can lead to pathology, such as autoimmunity that affects the gastrointestinal 
tract, the central nervous system, kidneys, skin, lungs, and joints (Ospelt, 2010).  Upon 
tissue damage or pathogen recognition, the inflammatory response is coordinated by 
activating various signaling pathways that regulate both pro-and anti-inflammatory 
mediators in resident tissue cells and leukocytes recruited from the blood (Lawrence, 
2009).  
Macrophages play an essential role in innate immunity as phagocytes, production 
of inflammatory cytokines, and initiation of the adaptive immune response by presenting 
antigens to T-lymphocytes (Janeway et al., 2001). Macrophages can be polarized into two 
different phenotypes, which have been historically described as classically activated (M1) 
and alternatively activated (M2) (Lee et al., 2020). M1 macrophages are typically 
induced by interferon-g (IFN-g) with a Toll-like receptor (TLR) agonist such as 
lipopolysaccharide (LPS) and are considered pro-inflammatory with the production of 
cytokines such as IL-1, IL-6, IL-12, and IL-23 (Lee et al., 2020). M2 macrophages are 
induced by T helper 2 (TH2) CD4+ T cells which produce IL-4, IL-10, and IL-13, and are 
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considered anti-inflammatory through the production of cytokines such as IL-10, IL-22, 
and TGF-b (Murray 2017, Lee et al. 2020). 
Different immune responses require M1 and M2 macrophages. Accordingly, M1 
and M2 macrophages must regulate cellular metabolism to provide appropriate 
metabolites to meet energy demands for distinct immune responses. The key difference 
between M1 and M2 macrophages is the metabolism of arginine. M1 macrophages 
metabolize arginine to nitric oxide (NO) and citrulline via nitric oxide synthase 2 (NOS-2 
or iNOS), these products are pro-inflammatory, cytotoxic, and increase the production of 
reactive oxygen species (ROS) and nitrogen species (Lee et al., 2020). M2 macrophages 
express ornithine decarboxylase and spermidine oxidase, which hydrolyzes arginine to 
produce ornithine and polyamine, suppressing pro-inflammatory responses (Lee et al., 
2020). Understanding macrophage cellular metabolism in response to stimuli can 
potentially be exploited to identify anti-inflammatory compounds.     
 
Indirubins role in inflammation 
 Severe and chronic inflammation can cause significant tissue damage and have 
previously been associated with numerous autoimmune diseases, cancer, and atopic 
disorders. Medicines that inhibit the signaling pathways of pattern recognition receptors 
(PRRs) such as TLRs can be considered potential anti-inflammatory agents. TLR-4, a key 
PPR, when activated by LPS, a principal component of Gram-negative bacteria’s outer 
membrane, triggers the downstream nuclear transcription factor kappa-B (NF-kB) 
signaling pathway. NF-kB regulates the production of various pro-inflammatory 
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cytokines and the expression of many genes encoding inflammatory mediators (Lai et al., 
2017).  
 NF-kB is one of the most important transcription factors in the inflammatory 
response and is commonly expressed by activated M1 macrophages. The activation of 
NF-kB involves the phosphorylation of IkBs at two serine residues (Ser32, Ser36) by the 
IkB kinase (IKK) complex (Kim et al., 2007). Once phosphorylated, IkBs are 
ubiquitinated and degraded by the 26S proteasome. The now free NF-kB translocates to 
the nucleus, binds to kB binding sites, and induces the transcription of pro-inflammatory 
mediators such as iNOS, Cox-2, TNF-a, IL-1b, IL-6, and IL-8 (Kim et al., 2007). 
Previous studies have shown that indirubin inhibits LPS-induced NF-kB P65 
phosphorylation in a dose-dependent manner via the inhibition of IkBa degradation (Lai, 
2017). Thus, indirubin potentially inhibits iNOS, Cox-2, TNF-a, IL-1b, IL-6, and IL-8 
production. Indirubin and structurally related compounds containing indole backbones 
need to be further explored to determine the therapeutic anti-inflammatory potential of 
these compounds. 
 
Aryl hydrocarbon receptor (AHR) 
The AHR is a member of the basic helix-loop-helix family of ligand-activated 
transcription factors. AHR is activated by a variety of ligands, including environmental 
pollutants (e.g., polycyclic aromatic hydrocarbons), tryptophan metabolites (e.g., 
kynurenic acid, 6-formylindolo[3,2-b]carbazole (FICZ)), as well as endogenous 
compounds such as indirubins and indole-containing compounds (Dvořák et al., 2021). 
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Depending on the structure-activity relationships (SARs) of the AHR ligand, the ligand is 
defined as full or partial agonists, or as an antagonist leading to differential binding 
affinity (Blažević et al., 2015). The stronger binding a ligand has to AHR, the longer-
lasting and toxic effects tend to be.  
Inactivated AHR resides within the cytoplasm in a complex with several 
chaperone proteins such as 90-kDa heat shock protein (HSP90), AHR-interacting protein 
(AIP), cochaperone p23, and the c-Src protein kinase (Gutiérrez-Vázquez, 2018). Once 
activated by a ligand, AHR dissociates from the chaperone protein complex and 
undergoes translocation into the cell nucleus. Nuclear AHR forms a heterodimer with the 
AHR nuclear translocator (ARNT). The heterodimeric AHR/ARNT binds the target DNA 
sequences known as xenobiotic response elements (XREs) and triggers the expression of 
drug-metabolizing enzymes such as cytochrome P450 enzymes like CYP1A1 and 
CYP1B1 (Dvořák et al., 2021).  
AHR activation by various indole-containing ligands has been linked to AHR 
recruitment to different target DNA sequences and ultimately triggering ligand-specific 
biological responses (Gutiérrez-Vázquez, 2018). Several different physiological 
processes have been linked to the activation of AHR, such as an inflammatory response 
(Gutiérrez-Vázquez, 2018), hematopoiesis (Boitano et al., 2010), as well as 
carcinogenesis (Kolluri, 2017). 
Indirubins have shown to interact with AHR to varying degrees; interactions tend 
to be brief due to indirubins’ metabolism in an AHR-dependent manner by cytochrome 
P450 enzymes such as CYP1A1 and CYP1B1 (Knockaert et al., 2004). However, 
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indirubin derivatives with high AHR affinity and low molecular stability can be an 
attractive therapeutic alternative compared to the traditional, more stable, and potentially 
toxic AHR ligands studied, such as 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) 
(Knockaert et al., 2004). 
 
The history of indirubins  
 Plants have been used for centuries to treat various ailments and diseases such as 
chronic inflammation.  Natural products may also serve as a basis for the synthesis of 
derivatives to reduce toxic side effects and improve pharmacokinetic properties and 
efficacy. Until recently, the majority of active compounds within these medicinal herbs 
were unknown. After extensive research of one such medicinal herb traditionally used to 
treat chronic myelocytic leukemia, Danggui Longhui Wan, it was found that the active 
compound was a stable red isomer of blue indigo known as indirubin (Hoessel et al., 
1999). Indirubin is chemically a 3,2’-bisindole commonly derived from tryptophan 
precursors (Blažević et al., 2015).  Naturally derived indirubins, as well as other indole-
containing compounds, have been shown to have anti-proliferative effects, mainly 
attributed to the inhibition of the cell cycle-related kinases, such as cyclin-dependent 
kinases (CDKs) and glycogen synthase kinase-3b (GSK-3b ) (Blažević et al., 2015). 
Indirubin derivatives and structurally related compounds containing an indole core have 
also been shown to have anti-inflammatory properties via inhibition of NF-kB nuclear 
translocation (Kim et al., 2010).  
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Indirubin derivative E804 
 Naturally occurring indirubins generally have low bioavailability due to the 
structure’s planarity, hydrogen bonds, and hydrophobic p-interactions. Accordingly, 
researchers have synthesized many artificial indirubin derivatives or structurally related 
compounds with improved chemical and pharmacological properties such as solubility 
and absorption (Busbee et al., 2013). One such indirubin derivative is indirubin-3’-(2,3 
dihydroxypropyl)-oximether (E804). E804 possesses novel inhibitory activity of signal 
transducer and activator of transcription 3 (STAT3) in human breast and prostate cancer 
cells through the direct inhibition of c-Src kinase activity (Nam et al., 2005). The c-Src 
kinase has a vital role in cell proliferation, tumorigenesis, and metastasis resulting in the 
phosphorylation of tyrosyl residues of critical cellular substrates and leading to the 
activation of oncogenic signal transduction pathways such as STAT3 (Nam et al., 2005). 
In addition to upregulating numerous genes involved in the activation of oncogenic signal 
transduction pathways, STAT3 induces the expression of many cytokines, chemokines, 
and other immune mediators, such as IL-6 and COX-2, that are associated with cancer-
promoting inflammation (Yu, 2009). Receptors for these pro-inflammatory mediators in 
turn further activate STAT3, forming autocrine and paracrine feed-forward loops that 
result in the promotion of cancer inflammation (Yu, 2009).  
 Interestingly, STAT3 also interacts with NF-kB on several levels. Many 
inflammatory factors encoded by NF-kB target genes, such as IL-6, are also critical 
STAT3 activators. In the context of pro-inflammatory tumor environments, STAT3 
directly interacts with the NF-kB family member RELA by trapping it in the nucleus, 
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which results in constitutive activation of NF-kB (Yu, 2009). These reports suggest an 
indirect mechanism by which STAT3 maintains the expression of genes encoding pro-
inflammatory mediators. Due to the pivotal role in which STAT3 influences the nature of 
pro-inflammatory environments, STAT3 inhibition by E804 and other structurally related 
compounds represent promising therapeutic compounds in alleviating inflammation.  
 
STATTIC 
 As alluded to above, STAT3 is a crucial transcription factor regulating immunity 
and inflammatory pathways (Yu, 2009). Constitutive activation of the STAT3 pathway 
has also been shown to lead to aberrant growth and survival of human tumors 
(Mcmurray, 2006). STAT3 transduces signals from IL-6 family cytokines, epidermal 
growth factors, platelet-derived growth factor, as well as others. When activated, the 
receptor becomes phosphorylated on the tyrosine residues, and STAT3 is recruited 
through its SH2 domain. Tyr705 of STAT3 then becomes phosphorylated by JAK 
kinases, Src-family kinases. On dissociation, two STAT3 molecules dimerize through 
reciprocal pTyr705-SH2 domain interactions, and the dimer translocates to the nucleus, 
where it initiates the transcription of various genes (Mcmurray, 2006). Thus, treatment 
with STAT3 inhibitors has been proposed as a potential therapy for several diseases and 
pathologies associated with chronic inflammation (Liu et al., 2018). 
 6-Nitrobenzo[b]thiphene 1,1-dioxide (STATTIC) has since been identified as one 
of the top candidates for selectively inhibiting the function of the STAT3 SH2 domain 
regardless of the STAT3 activation state in vitro (Schus et al., 2006). STATTIC inhibits 
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the binding of a relevant tyrosine-phosphorylated peptide motif to the STAT3 SH2 
domain. Consequently, STAT3 dimerization and DNA binding are inhibited by 
STATTIC, which has a minimal effect on other STAT family members such as STAT1, 
while inducing apoptosis of STAT3-dependent cancer cell lines (Schus et al., 2006). 
STATTIC has been shown to be an efficient radiosensitizing agent in normoxic and 
hypoxic esophageal squamous cell carcinoma cells by inhibiting STAT3 activation, and 
downregulating HIF-1a and VEGF expression (Zhang et al., 2015). Additionally, 
STATTIC inhibits RANKL-induced expression of osteoclast-related transcription factors 
c-Fos and NFATc1 induced by STAT3 and NF-kB, preventing bone loss caused by 
ovariectomy (Li et al., 2018). Taken together, the novel small nonpeptidic molecule 
STATTIC provides a potential avenue in the therapeutic application for the treatment of 
inflammatory diseases caused by STAT3 signaling.  
 
Hypothesis and aims  
 In the study described herein, I investigated the potential role of AHR 
antagonism in regulating the response of RAW 264.7 macrophages to a pro-inflammatory 
stimulus such as LPS. This study tested the hypothesis that AHR antagonism plays a 
critical role in mediating the therapeutic properties of indole-derived compounds E804 
and STATTIC. Additionally, I investigated the potential of STATTIC as an anti-






 The immune system protects the body from a broad range of insults via induction 
of an inflammatory response. Acute inflammation for instance, is critical for protection 
against microbial pathogens. However, unresolved or chronic inflammation can result in 
various types of pathology, including tissue damage, autoimmunity, atherosclerosis, 
inflammatory bowel diseases, and cancer progression (Ospelt, 2010; Doherty et al., 2003; 
Bouma and Strober, 2003; Multhoff et al., 2012).  Macrophages play an essential role in 
coordinating a balance between driving inflammation by producing pro-inflammatory 
mediators, including cytokines, and nitric oxide (NO) (Mantovani, 2006; Dall’Asta et al., 
2012; Janeway et al., 2001; Babcock et al., 2013), and resolution of inflammation via 
secretion of anti-inflammatory cytokines and mediators. 
 Macrophage activation by an inflammatory stimulus, such as lipopolysaccharide 
(LPS) from Gram-negative bacteria, is primarily recognized through pattern recognition 
receptors (PPRs) such as the Toll-like receptor 4 (TLR-4) (Lee et al., 2020). Following 
TLR-4 activation, several intracellular signaling events initiate through the adaptor 
molecules myeloid differentiation primary response gene 88 (MyD88), TIR-domain-
containing adapter-inducing interferon-b (TRIF), transforming growth factor-b (TGF-b)-
activated kinase (TAK1), and tumor-necrosis factor(TNF)-receptor-associated factor 6 
(TRAF6) (Akira and Takeda, 2004). In turn, these adaptor molecules activate several 
transcription factors including, nuclear transcription factor kappa-B (NF-kB) and signal 
transducer and activator of transcription 3 (STAT3) signaling pathways resulting in 
increased production of pro-inflammatory enzymes and cytokines, such as iNOS, COX-2, 
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TNF-a, IL-1b, IL-6, and IL-8. These pro-inflammatory mediators further promote the 
recruitment and activation of additional immune effector cells (Grivennikov and Karin, 
2010; Kim et al., 2007; Fu et al., 2020). In view of NF-kB and STAT3’s central role in 
driving inflammation, efforts have focused on inhibiting these pathways as a therapeutic 
approach to treat immune and inflammatory-mediated pathologies (Yu and Kone, 2004; 
Grivennikov and Karin, 2010; Li et al., 2018). 
 A promising avenue for discovering new anti-inflammatory therapeutics involves 
the naturally occurring compound indole, its metabolites, and synthetic derivatives. 
Indole is a planar bicyclic molecule in which the benzene ring is fused through 2 and 3 
positions of N-containing pyrrole ring (Sravanthi and Manju, 2016). The indole ring is 
widely distributed in biological systems as an essential constituent of biomolecules and 
natural products such as the essential amino acid tryptophan, plant hormones, alkaloids, 
and the neurotransmitter serotonin (Kumari and Singh, 2019). Due to its wide 
distribution, indole-based compounds have numerous biological activities and can 
function as anti-microbial, anti-convulsant, anti-cancer, and anti-inflammatory mediators 
(Sravanthi and Manju, 2016). A naturally-derived indole ring containing compound that 
has shown promising anti-inflammatory applications is indirubin and its derivatives 
(Chan et al., 2012; Miyoshi et al., 2012). Indirubin is chemically a 3,2’-bisindole 
commonly derived from tryptophan precursors (Blažević et al., 2015), and has shown to 
exhibit anti-leukemic, anti-proliferative, hepatoprotective, and strong anti-inflammatory 
properties (Babcock et al., 2013; Lai et al., 2017; Blažević et al., 2015). Despite 
indirubin’s natural therapeutic potential, poor solubility and absorption have led 
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investigators to design new indirubin derivatives to combat this problem (Busbee et al., 
2013).  
 Many indole ring-containing compounds, such as indirubin and several indirubin 
derivatives, have shown to have a high affinity for the aryl hydrocarbon receptor (AHR). 
The AHR is a member of the basic helix-loop-helix family of ligand-activated 
transcription factors and becomes activated by various xenobiotic and endogenous 
ligands (Nebert, 2017; Dvořák et al., 2021). Depending on structure-activity relationships 
(SARs), AHR ligands are defined as full agonists, partial agonists, and antagonists 
leading to differential binding affinity (Blažević et al., 2015). Upon activation, the AHR 
is recruited to different target DNA sequences and ultimately triggering ligand-specific 
biological responses (Gutiérrez-Vázquez, 2018). The most well-known of these genes in 
the fields of toxicology and pharmacology are the expression of drug-metabolizing 
enzymes such as cytochrome P450 enzymes, namely CYP1A1 and CYP1B1 (Guengerich 
et al., 2004; Dvořák et al., 2021; Köhle and Bock, 2007).  
The indirubin derivative, indirubin-3’-(2,3 dihydroxypropyl)-oximether (E804), 
possesses novel activity against STAT3 signaling through the direct inhibition of c-Src 
kinase activity and tyrosyl phosphorylation (Nam et al., 2005). E804 has also been shown 
to be a potent anti-inflammatory agent by inhibiting the expression of iNOS, IL-6, and 
COX-2 (Babcock et al., 2013). In addition to E804’s therapeutic potential via the STAT3 
pathway, E804 has been implicated in the activation of AHR in the human glioblastoma 
cell line T98-G (Babcock et al. 2013, Scobie 2019). Due to structural instability, E804 is 
quickly metabolized by enzymes induced through AHR activation, such as CYP1A1 and 
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CYP1B1 (Scobie, 2019; Spink et al., 2003). However, with the application of AHR 
antagonists such as 6,2’,4’-trimethoxyflavone (TMF), the metabolism of E804 can 
potentially be inhibited to enhance the anti-inflammatory properties of E804 as well as 
other indole containing compounds such as STATTIC.  
In the study described herein, I investigated the potential role of AHR antagonism 
in regulating the response of RAW 264.7 macrophages to a pro-inflammatory stimulus 
such as LPS. This study tested the hypothesis that AHR antagonism plays a critical role 
in mediating the therapeutic properties of indole-derived compounds E804 and 
STATTIC. Additionally, I investigated the potential of STATTIC as an anti-
inflammatory molecule and as an AHR ligand.  
 
MATERIALS AND METHODS 
 
Cells and cell culturing 
The murine macrophage cell line RAW 264.7 was obtained from ATCC ((# TIB-
71) Manassas, VA, USA) and cultured phenol red-free minimum essential media (MEM-
alpha; Gibco) supplemented with 10% fetal bovine serum (FBS; HyClone Thermo), 20 
mM HEPES (pH 7.5), 4 mM L-glutamine, 100 U/ penicillin, 100 µg/ streptomycin, 1 mM 
sodium pyruvate, 44 mM NaHCO3 (each from Sigma Aldrich), and 1% non-essential 
amino acid solution (100X, HyClone Thermo). Cells were typically grown to near 




E804 (Figure 1A) was obtained from Alexis Biochemical (CA, USA) and 
solubilized in dimethyl sulfoxide (DMSO) (Sigma Aldrich) to a stock solution of 10-2 M 
and stored at -20°C. The AHR antagonist TMF (Figure 1B) was purchased from Sigma-
Aldrich (MO, USA) and solubilized in DMSO to a stock solution of 10-2 M and stored at 
-20°C. STATTIC (Figure 1C) was obtained from Tocris (UK) and was solubilized in 
DMSO to a stock solution of 4.12 X 10-3 and stored at -20°C. Working dilutions were 
made with DMEM. 
 
 
Figure 1: Chemical structures for (A) indirubin-3’-(2,3 dihydroxypropyl)-oximether 





Cell viability was quantified as a function of succinate dehydrogenase activity, a 
measure of cellular respiration, by performing an MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide) assay. RAW264.7 macrophages were plated into 96 well 
Stattic 
A. B. C. 
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Costar plates at 106 cells per well in 100 µl of DMEM media. After 4 h of incubation at 
5% CO2 and 37°C for adherence, compounds and the carrier control DMSO were added 
in quadruplicates over serial dilutions beginning with 100 µM per well in a total volume 
of 200 µl. Plates were incubated for 24 h. Four hours before the end of the assay, 20 µl of 
5mg/mL MTT solution in DMEM was added to each well. The supernatant for each well 
was discarded, and cells containing reduced MTT solubilized with 100 µl of acidified 
isopropanol (4 mM HCl, 0.1% NP-40 in isopropanol). After a shaking period of 5 min, 
the optical density (O.D.) for each well was measured at 550 nm Synergy H1 Hybrid 
plate reader (BioTek). The experiment was repeated three times. For statistical purposes, 
data were compared between treatment groups using ANOVA and Bonferroni’s multiple 
contrast post-hoc tests using GraphPad 9 statistical package. Prior to experiments, a a 
value of 0.05 was established as statistically significant for cytotoxicity determinants and 
throughout this study. Based on these assays it was determined that 0.1 and 1 µM E804 
and STATTIC, and 10 µM TMF were suitable for further investigation.  
 
Phagocytosis assay 
The phagocytic capability of RAW264.7 macrophages following 24 h of 
compound treatment was determined by measuring phagocytosis of 1 µM fluorebrite 
carboxylate YG microspheres (Polyscience) diluted in 50 mM Na2HPO4. Washed beads 
were added to 105 treated cells in opaque flat-bottom 96 well plates at a ratio of 100:1 in 
a total of 200 µl of media, and plates incubated for 90 min at 37°C with 5% CO2. 
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Phagocytosis was stopped by performing 3 washes with 100 µl of ice-cold 0.01 M 
phosphate-buffered saline (PBS) containing 1 mM CaCl2 and MgCl2. Extracellular 
fluorescence was quenched with trypan blue (2 mg/ml) dissolved in 20 mM citrate and 
150 mM NaCl with a pH of 4.5. Plates were then read with a Synergy H1 Hybrid plate 
reader (BioTek) at an excitation wavelength of 441 nm and an emission wavelength of 
486. Data were compared between treatment groups using ANOVA, followed by 
Bonferroni’s post-test using GraphPad 9 statistical package. The experiment was repeated 
three times. 
 
AHR Reporter Assay  
AHR-reporter assay was performed using a Human AHR Reporter Assay system 
(Indigo Biosciences). The AHR Reporter cells express luciferase under the AHR 
promoter. The AHR reporter cells were treated in triplicate with serial dilutions of 
STATTIC, E804, and MeBIO, a known AHR agonist and positive control included in the 
kit, in the presence or absence of TMF. Following a 24 h incubation period at 37°C with 
5% CO2, relative luminescence units (RLU) were measured using Synergy H1 Hybrid 
plate reader (BioTek). RLU data were subjected to a nonlinear regression (curve fit) 
model using the [agonist] versus response (three parameters) equation for each treatment 
and plotted on a log10 scale using GraphPad 9 statistical package. Additionally, TMF and 
E804 antagonist RLU data were normalized individually and presented as a maximum 
activity percentage. This data was then subjected to a nonlinear regression (curve fit) 
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model using the [inhibitor] versus response (three parameters) equation and plotted on a 
log10 scale using GraphPad 9 statistical package. 
 
 
Measuring NO production 
Nitric oxide (NO) production by LPS-stimulated RAW264.7 macrophages is a 
reliable screening assay for the anti-inflammatory properties of new pharmacological 
compounds of interest (Silva et al., 2021). Therefore, this assay was used to demonstrate 
the anti-inflammatory activity of E804, STATTIC, and TMF. RAW264.7 macrophages 
were plated in 96 well Costar plates at 106 cells per well in 100 µl of phenol-free DMEM-
alpha media (Gibco). Following a 3 h incubation period at 37°C with 5% CO2 for 
adherence, phenol-free DMEM media was replaced, and cells treated with E804 (0.1, 1 
µM), STATTIC (0.1, 1 µM), in combinations with both TMF (10 µM), LPS (0.1 µg/ml), 
or neither in a final volume of 200 µl in triplicates. After 24 h, supernatants were 
harvested and 100 µl transferred to a 96-well plate for determination of NO2 production, 
a stable non-volatile product of NO production, measured using an equal volume of 
Griess reagent (0.1% N-(1-naphthyl)-ethylenediamine, and 1% sulfanilamide in 5% 
H3PO4 solution) at room temperature for 10 min. The O.D. was measured with a Synergy 
H1 Hybrid plate reader (BioTek) at 550 nm and compared to a NaNO2 standard curve. 
Values per replicate were averaged and then plotted. Nitrite concentrations were 
compared between treatment groups using ANOVA, followed by Bonferroni’s post-test 
using GraphPad 9 statistical package.  
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 iNOS protein expression was also quantified by immunocytochemistry that 
determined the relative amount of iNOS protein expressed in cells. RAW264.7 
macrophages were plated into 96 well Costar plates at 105 cells per well in 100 µl of 
DMEM media. After 4 h of incubation at 37°C with 5% CO2 for adherence, macrophages 
were treated for 24 hr with compounds of interest. The overlying media was then 
removed and wells were washed 3 times with PBS containing 0.1% tween-20 (PBS-
TW20). Each well then received 200 µl ice-cold methanol for 15 min to fix cells attached 
to the wells followed by another round of washing 3 times with PBS-TW20. Each well 
was then blocked with 10% FBS in PBS overnight. Blocking buffer was then removed 
and washed once with PBS-TW20. Cells were then incubated with rabbit anti-mouse 
iNOS antibody (BD Transduction Labs, 1:500 dilution) for 24 h. Following three washes 
with PBS-TW20, macrophages were incubated for an additional hour with a secondary 
goat anti-mouse IgG (H+L) antibody conjugated with Alex Fluor Plus 488 
(ThermoFisher) at room temperature in the dark. The relative fluorescence units (RFU) 
for each well was determined at ex/em of 495-515 nm. Data were compared between 
treatment groups using ANOVA, followed by Bonferroni’s post-test using GraphPad 9 
statistical package. 
 
Measuring intracellular reactive oxygen species (ROS) production 
RAW264.7 macrophages were plated into 96 well Costar plates at 105 cells/well 
in 100 µl of DMEM media for 3 hours and then treated with E804 (1 or 0.1µM), 
STATTIC (0.1, 1µM), in the presence or absence of TMF (10 µM) and LPS (0.1 µg/ml). 
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After 24 h of incubation at 5% CO2 and 37°C, dichlorofluorescin diacetate (DCFDA) 
(molecular Probes, Eugene OR) was added at 10-5 M to all wells and incubated for an 
additional 30 min at 5% CO2 and 37°C to detect total superoxide. The plates were 
washed three times with PBS-TW20. The plates were read at ex/em 485-530 nm. RFU’s 
were subject to a comparison between treatment groups using ANOVA, followed by 
Bonferroni’s post-test using GraphPad 9 statistical package. 
 
IL-6 enzyme-linked immunosorbent assay (ELISA) 
An ELISA MAXTM Deluxe Sets for Interleukin-6 (IL-6) secreted by RAW264.7 
macrophages following treatment at 6 and 24 h. 100 µl of supernatants from 
macrophages treated with E804 (1, 0.1µM), STATTIC (0.1, 1µM), and in combination 
with or without TMF (10 µM) or LPS (0.1 µg/ml) were used as the source. A 
commercially available mouse IL-6 ELISA MAX Deluxe Set (Biolegend) was used for 
IL-6 cytokine assays. Supernatants were added to a pre-coated capture antibody Costar 
maxi-sorb plate provided by the kit and incubated overnight at 4°C. The plates were 
washed and blocked using reagents provided by the vendor. Detection antibody was 
added for 1 hour, followed by treatment with avidin-HRP and a colorimetric substrate 
solution. A phosphoric acid stop solution was added, and the plates were read at 450 nm. 
Concentrations of cytokines were plotted against the standard curve of known 
concentrations supplied by the manufacturer and expressed as relative concentrations 





Defining the cytotoxicity of E804, STATTIC, and TMF  
Initially, I defined a concentration range of E804, STATTIC, and TMF that did 
not affect RAW264.7 macrophage viability. For this purpose, an MTT assay, which 
measures succinate dehydrogenase activity and cellular respiration level (Tim, 1983) was 
employed. RAW264.7 macrophages were cultured for 24 h with varying concentrations 
of E804, STATTIC, and TMF and cellular respiration measured. Up to 3 µM of E804 and 
up to 1 µM STATTIC was seen to have no effect on RAW264.7 macrophage cellular 
respiration (Figure 2A,B). Similarly, up to 25 µM of TMF (Figure 3C) had no effect on 
cellular respiration. Therefore, a maximum of 1 µM E804, 0.1 µM STATTIC, and 25 µM 
TMF was used for subsequent assays.  
 
Figure 2: Effects of (A) indirubin-3’-(2,3 dihydroxypropyl)-oximether (E804), (B) 
6,2’,4’-trimethoxyflavone (TMF), (C) 6-nitrobenzo[b]thiophene 1,1-dioxide  (STATTIC) 
on cellular respiration in RAW264.7 macrophages, as determined by the MTT assay. 
Data represent the percent change in O.D. compared to control, shown as mean ± 


























































































































) TMF MTT Assay - 24 h
A. B. C.
 20 
Defining the AHR activity of E804, STATTIC, and TMF 
To determine if E804, STATTIC, and TMF were AHR ligands, a human AHR 
cell-based genetic reporter assay was used. As expected, the AHR agonist MeBio induced 
a significant dose-dependent increase in AHR activity (Figure 3A). Even though reduced 
relative to MeBIO stimulation, E804 induced significant AHR activation (Figure 3B), 
which peaked at approximately 80 nM but diminished with an increasing concentration 
(Figure 3B). On the other hand, TMF elicited only weak AHR activity at high 
concentrations (e.g. 2 µM) (Figure 3C), whereas STATTIC failed to induce any AHR 
activation (Figure 3D). These findings indicate that: i) E804 is an AHR agonist, ii) TMF 
despite being a known AHR antagonist, can stimulate weak AHR activity at high 
concentrations, and iii) STATTIC is not an AHR ligand, as measured in this reporter 
assay.  
To determine the antagonistic properties of TMF, TMF was serially diluted and 
used in combination with E804 (EC85 value of 76 nM). The results indicate that TMF 
inhibited AHR activation at 80 nM and below. At 400 nM and above, TMF showed 
partial AHR activity (Figure 4). These results suggest that TMF is an AHR antagonist, 
blocking E804-dependent AHR activation by competitively binding to AHR at lower 
concentrations. At higher concentrations, TMF still competitively binds to AHR but is a 






Figure 3: Effect of 24-h treatment with indirubin-3’-(2,3 dihydroxypropyl)-oximether 
(E804), 6-nitrobenzo[b]thiophene 1,1-dioxide  (STATTIC), 6,2’,4’-trimethoxyflavone 
(TMF), or MeBIO on AHR activity. (A) MeBIO showed a normal dose-response curve. 
(B) E804 showed AHR agonist activity. (C) TMF showed partial agonist activity at 
higher a higher concentration. (D) STATTIC showed no AHR agonist activity. Data 
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Figure 4: Effect of 24-h treatment with AHR antagonist 6,2’,4’-trimethoxyflavone 
(TMF), on the AHR activity of indirubin-3’-(2,3 dihydroxypropyl)-oximether (E804) 
(EC85 76 nM) in a human AHR cell-based genetic reporter assay. TMF inhibited E804-
dependent AHR activation at lower concentrations. At higher concentrations, TMF 
showed partial agonist activity. Data represents normalized mean luminescence units ± 
standard error (n = 3 individual experiments). 
 
 
Evaluation of the effects of E804, STATTIC, and TMF on NO production 
iNOS enzymatic activity is readily induced in macrophages stimulated with LPS. 
With this in mind, I initially assessed the effect of TMF on iNOS enzymatic activity 
following stimulation of RAW264.7 macrophages with 0.1 µg/ml of LPS. iNOS activity 
was suppressed ~50% by 10 mM of TMF (Figure 5). Next, I examined the impact of 
combining TMF with E804 and STATTIC on LPS-induced iNOS activity. E804 and 
STATTIC alone significantly reduced NO production in a dose-dependent manner 
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(Figure 6). Strikingly, the addition of TMF markedly increased the inhibitory effects of 
E804 and STATTIC (Figure 6). This was readily detected at low concentrations (0.1 
mM) of E804 and STATTIC; namely 10 mM of TMF increased the inhibitory effect of 
STATTIC and E804 by ~3 and 2-fold, respectively (Figure 6). Under the present 
experimental conditions, it can be suggested that E804, STATTIC, and TMF play a role 














Figure 5: Effects of 6,2’,4’-trimethoxyflavone (TMF) on iNOS enzymatic activity in 
RAW264.7 macrophages stimulated with 0.1 µg/ml lipopolysaccharide (LPS) using the 
Greiss reagent assay. TMF reduced iNOS activity in a dose-dependent manner. 
Compound concentrations are in µM. (*p < 0.05, ***p < 0.001, ****p < 0.0001). Data 
represent percent change in O.D. compared to LPS, shown as mean ± standard error (n = 
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Figure 6: Effects of 24-h treatments with indirubin-3’-(2,3 dihydroxypropyl)-oximether 
(E804), 6-nitrobenzo[b]thiophene 1,1-dioxide  (STATTIC), and/or 6,2’,4’-
trimethoxyflavone (TMF), and/or 0.1 µg/ml lipopolysaccharide (LPS), or no treatment 
(control) on iNOS enzymatic activity in RAW264.7 macrophages using the Greiss 
reagent assay (A, B) STATTIC reduced iNOS activity in a dose-dependent manner, and 
co-treatment with TMF enhanced the inhibitory effect. (C, D) E804 reduced iNOS 
activity in a dose-dependent manner, and co-treatment with TMF enhanced the inhibitory 
effect. Compound concentrations are in µM. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p 
< 0.0001). Data represent percent change in O.D. compared to LPS, shown as mean ± 
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Defining the effects of E804, STATTIC, and TMF on cellular iNOS protein expression  
As expected, LPS was a potent inducer of iNOS protein expression (Figure 7). On 
the other hand, neither E804, STATTIC, nor TMF alone upregulated iNOS protein 
expression (Figures 7 and 8). STATTIC alone, however, was observed to significantly 
reduce LPS-stimulated iNOS expression in a dose-dependent manner (Figure 8). 
Interestingly, the addition of TMF (10 µM) failed to enhance the inhibitory effect of 
STATTIC on LPS-induced iNOS expression (Figure 8A, B). E804 reduced LPS-induced 
iNOS protein expression only at the high (1 µM) versus low (0.1 µM) concentrations 
tested (Figure 8C). Furthermore, co-treatment with TMF (10 µM) had no marked effect 
on E804 inhibition of iNOS expression (Figure 8D). These results indicate that E804 and 
STATTIC reduce iNOS protein expression, thereby reducing NO production. However, 
TMF does not reduce iNOS protein expression, suggesting an alternative mechanism in 




















Figure 7: Effects of 24-h treatments with 6,2’,4’-trimethoxyflavone (TMF), and/or 0.1 
µg/ml lipopolysaccharide (LPS), or no treatment (control) on iNOS protein expression in 
RAW264.7 macrophages. LPS induced iNOS protein expression, TMF+LPS is 
comparable to LPS. Compound concentrations are in µM. (**p < 0.01). Data represents 
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Figure 8: Effects of 24-h treatments with indirubin-3’-(2,3 dihydroxypropyl)-oximether 
(E804), 6-nitrobenzo[b]thiophene 1,1-dioxide  (STATTIC), and/or 6,2’,4’-
trimethoxyflavone (TMF), and/or 0.1 µg/ml lipopolysaccharide (LPS), or no treatment 
(control) on iNOS protein expression in RAW264.7 macrophages. (A, B) STATTIC 
reduced iNOS protein expression in a dose-dependent manner. (C) E804+LPS, 
E804+TMF+LPS, iNOS protein expression was comparable to LPS. (D) E804 reduced 
iNOS protein expression comparable to control. The addition of TMF had no significant 
effect. Compound concentrations are in µM. (*p < 0.05, ***p < 0.001, ****p < 0.0001). 
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Defining the effects of E804, STATTIC, and TMF on ROS production 
To further assess the effects of E804, STATTIC, and TMF on the LPS-induced 
inflammatory function of RAW264.7 macrophages, total ROS production was measured 
using a fluorescence-based assay. Unstimulated RAW264.7 macrophages exhibited 
constitutively high ROS production, which was increased following LPS stimulation 
(Figure 9). TMF alone did not increase ROS production (Figure 9). Furthermore, in LPS 
activated RAW264.7 macrophages, TMF co-treatment appeared to limit the LPS-induced 
increase in ROS, although this effect was not statistically significant (Figure 9). 
Both STATTIC and E804 had distinct effects on ROS production. The low (0.1 
mM) but not the high (1.0 mM) concentration of STATTIC inhibited the LPS-induced 
increase in ROS synthesis (Figure 10A,B).  On the other hand, E804 at the high (1.0 mM) 
but not the low (0.1 mM) concentration inhibited both constitutive and the LPS-induced 
increase in ROS production (Figure 10C, B). Co-treatment with TMF had no significant 
effect on STATTIC and E804-mediated ROS synthesis inhibition (Figure 10). These 
results suggest that E804 and STATTIC either inhibit NADPH-oxidase activities that 























Figure 9: Effect of 24-h treatments with 0.1 µg/ml lipopolysaccharide (LPS), 6,2’,4’-
trimethoxyflavone (TMF) 10 µM, TMF+LPS, or no treatment (control) on general 
reactive oxygen species production in RAW264.7 macrophages. TMF had no significant 
impact on ROS production. Data represents mean fluorescent units ± standard error (n = 
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Figure 10: Effects of 24-h treatments with indirubin-3’-(2,3 dihydroxypropyl)-oximether 
(E804), 6-nitrobenzo[b]thiophene 1,1-dioxide  (STATTIC), and/or 6,2’,4’-
trimethoxyflavone (TMF) 10 µM, and/or 0.1 µg/ml lipopolysaccharide (LPS), or no 
treatment (control) on general reactive oxygen species production in RAW264.7 
macrophages. (A) STATTIC reduced oxidative stress comparable to control. (B) 
STATTIC induces oxidative stress comparable to LPS. (C) E804 induces oxidative stress 
comparable to LPS. (D) E804 reduced oxidative stress below control. Compound 
concentrations are in µM. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Data 
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RAW264.7 macrophage phagocytosis is inhibited by E804 and STATTIC 
To further characterize the effects of compound treatment on macrophage 
function, phagocytosis of latex beads was investigated. Phagocytosis was enhanced by 
treatment with LPS (Figure 11B). Treatment with either 0.1 or 1.0 mM of STATTIC 
alone suppressed RAW264.7 macrophages' ability to phagocytize latex beads (Figure 
11A). Interestingly, at 0.1 µM, E804 increased macrophage phagocytosis, whereas at 1.0 
µM, phagocytosis was significantly reduced (Figure 11A).  TMF alone had no marked 
effect on bead phagocytosis (Figure 11A). In LPS stimulated macrophages, the addition 
of TMF did not further suppress macrophage phagocytosis in all treatments (Figure 11B).  
These results suggest that E804 and STATTIC impact macrophage function during the 








Figure 11: Effects of 24-h treatments with indirubin-3’-(2,3 dihydroxypropyl)-oximether 
(E804), 6-nitrobenzo[b]thiophene 1,1-dioxide  (STATTIC), and/or 6,2’,4’-
trimethoxyflavone (TMF), and/or 0.1 µg/ml lipopolysaccharide (LPS), or no treatment 
(control) on phagocytosis activity in RAW264.7 macrophages. (A) phagocytosis is 
increased by E804 0.1 µM, while phagocytosis in inhibited by STATTIC and E804 1 
µM. (B) Phagocytosis is stimulated by LPS and E804 0.1 µM+TMF, while phagocytosis 
is inhibited by STATTIC and E804 1 µM. Compound concentrations are in µM. (*p < 
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Data represent percent change in RFU 
compared to control, shown as mean ± standard error (n = 3 individual experiments). 
 
 
LPS-induced IL-6 secretion is suppressed by E804 and STATTIC 
IL-6 is a key cytokine that contributes to an inflammatory response. Accordingly, 
I assessed the effects of the compounds on LPS-stimulated IL-6 secretion by RAW264.7 
macrophages. As expected, LPS induced IL-6 secretion in macrophages after 6 h and 24 
h (Figures 12, 13). Alone, E804, STATTIC, and TMF did not induce IL-6 secretion 
(Figures 14, 15). In contrast, TMF alone after 24 but not 6 h significantly reduced IL-6 
production elicited by LPS stimulation (Figures 12, 13). In addition, both STATTIC and 
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RAW264.7 macrophages, and to a greater extent than TMF (Figure 13). Of note, TMF 
combined with 0.1 µM E804 reduced IL-6 secretion 4-fold at 24 h (Figure 15C). 
However, under the other co-treatment conditions tested, TMF had no effect on E804 and 
STATTIC inhibition of IL-6 secretion. Under the present experimental conditions, E804 
and STATTIC may mediate the production of IL-6 through inhibition of a common 





























Figure 12: Effects of treatments on the secretion of IL-6 in RAW264.7 macrophages. 
Cells were stimulated with 0.1 µg/ml lipopolysaccharide (LPS) 24 h and then treated with 
either control (no treatment) or 6,2’,4’-trimethoxyflavone (TMF) 10 µM alone for 6 h. 
LPS stimulated IL-6 secretion above control, TMF alone did not stimulate IL-6 secretion, 
TMF+LPS increased IL-6 secretion compared to LPS alone (****p < 0.0001). Data 
represent percent change compared to LPS (300 pg/mL), shown as mean ± standard error 
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Figure 13: Effects of 24-h treatments with 0.1 µg/ml lipopolysaccharide (LPS), 6,2’,4’-
trimethoxyflavone (TMF) 10 µM, TMF+LPS, or no treatment (control) on IL-6 secretion 
in RAW264.7 macrophages. LPS stimulated IL-6 secretion above control, TMF alone did 
not induce IL-6 secretion, TMF+LPS reduced IL-6 secretion compared to LPS alone. 
(***p < 0.001). Data represent percent change compared to LPS (300 pg/mL), shown as 
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Figure 14: Effects of 6-h treatments with indirubin-3’-(2,3 dihydroxypropyl)-oximether 
(E804), 6-nitrobenzo[b]thiophene 1,1-dioxide  (STATTIC), and/or 6,2’,4’-
trimethoxyflavone (TMF) 10 µM, and/or 0.1 µg/ml lipopolysaccharide (LPS), or no 
treatment (control) on IL-6 secretion in RAW264.7 macrophages. (A, B) LPS stimulated 
IL-6 secretion above control, while STATTIC reduced IL-6 in a dose-dependent manner. 
(C, D) E804 reduced IL-6 in a dose-dependent manner. Compound concentrations are in 
µM. (****p < 0.0001). Data represent percent change compared to LPS (300 pg/mL), 
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Figure 15: Effects of 24-h treatments with indirubin-3’-(2,3 dihydroxypropyl)-oximether 
(E804), 6-nitrobenzo[b]thiophene 1,1-dioxide  (STATTIC), and/or 6,2’,4’-
trimethoxyflavone (TMF) 10 µM, and/or 0.1 µg/ml lipopolysaccharide (LPS), or no 
treatment (control) on IL-6 secretion in RAW264.7 macrophages. (A, B) LPS stimulated 
IL-6 secretion above control, while STATTIC reduced IL-6 secretion comparable to 
control. (C) E804+TMF+LPS IL-6 secretion was comparable to LPS alone. (D) 
E804+LPS was comparable to control. Compound concentrations are in µM.  (*p < 0.05, 
**p < 0.01, ****p < 0.0001). Data represent percent change compared to LPS (300 
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In this study, I examined the effects of AHR antagonism on mediating the anti-
inflammatory properties of the indole-derived compound E804. Similarly, I examined the 
potential use of the indole-derived compound STATTIC as an anti-inflammatory 
molecule and as an AHR ligand. For these analyses, the murine macrophage cell line 
RAW264.7 was employed. RAW264.7 cells provide a well-established model to study 
macrophage pro-inflammatory function. 
Indole derivatives are important heterocyclic compounds in drug-discovery 
studies. This class of molecules play a significant role in cell biology and are naturally 
derived. Indole-containing compounds have gained significant interest in the use against 
cancer cells, inflammation, and a multitude of disorders in the human body (Kaushik et 
al., 2013). However, indole-containing compounds’ interactions with the AHR and the 
resulting immune modulation have been well documented (Dvořák et al., 2020). 
Therefore, E804, STATTIC, and TMF were evaluated for AHR activity. As previously 
described, E804 induced the gene transcription of the drug-metabolizing enzymes 
CYP1A1 and CYP1B1, which suggested AHR activity (Scobie et al., 2019; Babcock et 
al., 2013). In the study described herein, I confirm that E804 is an AHR ligand using a 
human AHR reporter assay. E804 is an AHR agonist with a moderate binding activity. To 
our knowledge, there has been no previous research on STATTIC as an AHR ligand. This 
study determined that STATTIC has no AHR activity, indicating that it is not an AHR 
ligand. In previous studies, TMF was shown to exhibit no partial agonist capabilities, 
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exhibiting the functional characteristics of a true AHR antagonist through repressing 
AHR-mediated gene induction (Murray et al., 2010). However, in this study, I show that 
TMF acts as a partial agonist at higher concentrations.  
As shown in this study with E804 and previous research efforts, indole-derived 
compounds are commonly AHR ligands (Dvořák et al., 2021). However, AHR activation 
results in the expression of drug-metabolizing enzymes such as cytochrome P450 
enzymes like CYP1A1 and CYP1B1, leading to the degradation of these ligands in an 
AHR-dependent manner (Spink et al., 2003). In this study, I showed that by inhibiting the 
activation of AHR and the resulting transcription of drug-metabolizing enzymes via 
TMF, rapid metabolism of E804 and STATTIC was inhibited in an AHR-dependent 
manner. Therefore, AHR antagonism should be further explored when evaluating the 
efficacy of future drug treatments.  Additionally, knowing that STATTIC has no AHR 
activity can be used to eliminate concerns over unnecessary immune modulation via 
AHR activation in future studies. 
Using LPS activated macrophages is a standard model used for understanding 
primary immune responses to Gram-negative bacteria. Typically, LPS initiates an 
immune response through TLR4 activation, initiating NF-kB signaling. In response, NF-
kB drives the expression of potent pro-inflammatory mediators and cytokines such as 
iNOS and IL-6 (Bagaev et al., 2019). iNOS enzymatic activity contributes to oxidative 
stress through the production of NO. NO combined with superoxide anion yields 
peroxynitrite, a potent long-lived free radical capable of disrupting surrounding tissues. 
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In this study, I observed the reduction of LPS-induced iNOS protein expression, 
NO production, and IL-6 secretion by E804 and STATTIC in a dose-dependent manner. 
Notably, the reduction in the expression of these inflammatory mediators was not due to 
RAW264.7 macrophage death. The concentrations of E804 and STATTIC used in the 
respective assays were determined to have no effect on RAW264.7 macrophage viability. 
The reduction in these pro-inflammatory mediators by E804 and STATTIC suggests a 
mechanism of action targeting the NF-kB signaling pathway, which regulates TLR-4 
signaling and expression of proinflammatory mediators such as iNOS activity, IL-6, IL-
12, COX-2, TNF- α, and IL-b. It should be noted that E804 and STATTIC may have 
distinct effects on the NF-kB pathway that include, for instance, inhibition of IkBa 
phosphorylation (Miller et al., 2010). Additionally, with the inclusion of the AHR 
antagonist TMF, inhibition of NO production by STATTIC and E804 was enhanced, 
although this effect did not correlate with a further decrease in iNOS protein expression. 
Interestingly, AHR antagonism by TMF on LPS stimulated RAW246.7 macrophages 
increased secretion of IL-6 at 6 h and decreased secretion at 24 h, suggesting that AHR 
activity may be beneficial in early inflammatory responses. These results also indicate 
that AHR antagonism may have a role in mediating the anti-inflammatory properties of 
indole-containing compounds. 
The complex biochemistry of NO production provides many potential sites for 
regulatory action. The biosynthesis of NO in macrophages is carried out as a byproduct 
from L-arginine to L-citrulline through the enzymatic activity of iNOS (Aktan, 2004). 
The reduction observed in NO production by TMF and not in iNOS protein expression 
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could be due to the alteration of iNOS enzymatic ability mediated by TMF interactions. 
Previous research efforts have indicated that flavones and flavone derivatives reduce NO 
production by directly scavenging NO radicles as well as directly inhibiting iNOS 
enzymatic activity (Sheu et al., 2001; Aktan, 2004). Overall, it is clear that future studies 
are needed to characterize the mechanisms in which TMF reduces NO production. 
Oxidative stress plays an essential role during the inflammatory response. When 
cellular production of ROS overwhelms its antioxidant capacity, it leads to a state of 
oxidative stress, contributing to the pathogenesis of several diseases (Lingappan, 2018). 
The effect of E804, STATTIC, and TMF on oxidative stress was monitored by ROS 
assays in which LPS-induced superoxide radical production was quantified. Under the 
conditions explored in this study, E804 (1 µM) and STATTIC (0.1 µM) significantly 
reduced ROS production during macrophage activation by LPS. AHR antagonism by 
TMF however, did not affect ROS production. AHR has multiple roles in ROS 
production. Previous research has indicated that AHR promotes ROS production by 
inducing gene expression of p40phox, a subunit for nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase, which is a crucial enzyme in ROS production (Vogel et al., 
2020). Furthermore, it has been shown that activation of AHR transcriptionally activates 
nuclear factor erythroid 2-related factor 2 (NRF2), a critical transcriptional factor that 
mediates antioxidative enzymes such as superoxide dismutase (Ma et al., 2004). The 
apparent varying roles of AHR in ROS production may explain the minimal effect of 
TMF treatment. Future studies are needed to define the role AHR has in ROS production 
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fully. This data suggests that E804 and STATTIC should be further explored to mediate 
oxidative stress during the inflammatory response.  
An indication of proper macrophage function includes the cell’s ability to 
phagocytize particles properly. As demonstrated in the experiment described herein, 
macrophage phagocytosis was markedly reduced by both E804 and STATTIC. E804 in 
lower concentrations (0.1 µM) significantly increased phagocytosis in LPS-stimulated 
macrophages as well as non-stimulated macrophages. This result was interesting because 
at a higher concentration (1 µM), phagocytosis was inhibited completely. This inhibition 
may be attributed to E804’s modulation of GSK-3b, which is involved in cytoskeletal 
changes during engulfment (Cabello et al. 2010). To our knowledge, this is the first study 
to examine the effects of STATTIC on the ability to mediate phagocytosis in RAW264.7 
macrophages. STATTIC inhibited phagocytosis in RAW264.7 macrophages, and this 
inhibitory action is potentially due to STATTIC’s high binding affinity to cysteine 
residues as seen in the inhibition of STAT3 (Heidelberger et al., 2013). STATTIC most 
likely binds to a cysteine residue in the target-binding cleft in actin, preventing actin 
filaments' formation during phagocytosis (Otterbein, 2001). However, STATTIC’s direct 




 This study suggests that the indole-containing compounds E804 and STATTIC 
are promising immunomodulating compounds with potent negative effects on iNOS 
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protein expression, NO production, IL-6 secretion, and macrophage phagocytic mediating 
capabilities. Additionally, this paper supports the use of E804 and STATTIC in 
combination with TMF to antagonize the degradation of these compounds in an AHR-
dependent manner. E804 and STATTIC may also possess valuable anti-inflammatory 
properties via inhibition of the NF-kB signaling pathway. However, future studies are 
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